Back to Results

Protocol A011-13 (HYPERION): A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients

Primary Objective

To evaluate the effects of sotatercept treatment versus placebo on TTCW in participants who are newly diagnosed with PAH and are at intermediate or high risk of PAH progression.

Study category: Heart and Blood Conditions

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Scope

National

Location

University of Colorado Hospital

Principal Investigator
David Badesch,  MD

David Badesch, MD

Study ID

Protocol Number: 21-3600

More information available at ClinicalTrials.gov: NCT04811092

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers